We see a growing number of small biotechs that choose to bring their products to the market themselves. In this article we explain how a CDMO can help them navigate clinical CMC hurdles, including bioprocess scale-up and preparing for what may be their first-ever BLA filing.
You may also be interested in:
Microbial
Difficult to Express Proteins
Fabs, Fusion, Scaffold and other Recombinant Proteins
Clinical Supply Services
Commercial Supply Services
Ibex® Dedicate
IND-to-BLA
Manufacturing: cGMP
Manufacturing: GMP Drug Substance
Process Development and Optimization
Read this article

View now
Latest content
Latest briefing from the Knowledge Center
Webinar (on-demand)
Charting a Successful CMC Journey for Your ADC Drug Product
Bioconjugates and Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their...
ADC vial with gradient background - close crop
Interview
Expert Q&A: Accelerate Your ADC Journey
Filling the Need for Integrated Bioconjugate Solutions Antibody drug conjugates (ADCs) are...
KC Video thumbnail
Video
mRNA and LNP Encapsulation Capabilities at our Geleen/NL Center of Excellence
Discover how our team, with its impressive mRNA/LNP track record, can help you progress your...
Mammalian Biologics Drug Substance Manufacture MC1
Article
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be...
Webinar (on-demand)
Early Preclinical Development of mRNA/LNP Projects, Transitioning Successfully to cGMP...
View our on-demand webinar exploring the development steps that lead to an mRNA construct optimized...
Webinar (on-demand)
Enhanced GS® CHO Vector Technology for Improved Expression Control of Biotherapeutic Proteins
Many of today’s expression platforms for recombinant protein production have been optimised for the...
man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough
Webinar (on-demand)
Integrating a High Sensitivity Immunopeptidomics (MAPPs) Assay in Preclinical Immunogenicity Risk...
Immunogenicity poses a critical risk to all biologics, including monoclonal antibodies, ADCs,...
Webinar (on-demand)
Navigating Biopharma Commercialization: The Interplay of Regulatory Affairs, Process Development and...
This on-demand webinar explores the essential alignment between regulatory affairs, process...
Biologics_Portsmouth_060
Article
Considerations for Successful Tech Transfer of a Biologics Upstream Process
In this European Pharmaceutical Review article, bioprocess experts from Lonza discuss how molecular...
e-book
Experts in Expression: Recent Advances in CHO Upstream Bioproduction
Constantly evolving biopharmaceutical pipelines require continuous evolution of CHO-based...
Article
Powering the Development of Tomorrow’s Bispecific Antibodies
bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct...
Webinar (on-demand)
Tech Transfer Strategies and Best Practices to Optimize Your Clinical and Commercial Supply
Tech Transfers for biological products, whether they occur from a pharma company, another CMO, or a...